DC Chemicals · Product datasheet

CB-5083 — Datasheet

CAT. NO. DC8840

Product page and current package options

ParameterValue
Chemical NameCB-5083
CAS No.1542705-92-9
SynonymsCB-5083;CB5083;591IV6UL6J;AK173785;1-(4-(benzylamino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide;1-[4-(benzylamino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl]-2-methyl-1H-indole-4-carboxamide;BCP23807;CB 5083;S8101;J3.551.815K;1-(7,8-Dihydro-4-((phenylmethyl)amino)-5H-pyrano(;1542705-92-9;CCG-268805;BDBM50500325;p97 Inhibitor CB-5083;HY-12861;UNII-591IV6UL6J;BRD-K49048664-001-02-0;CB-5083; CB 5083;EX-A773;MFCD28963914;BRD-K49048664-001-01-2;(1-(4-(benzylamino)-5H,7H,8H-pyrano(4,3-d)pyrimidin-2-yl))-2-methyl-1H-indole-4-carboxamide;DTXSID801022542;BC177445;1-[4-(benzylamino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl]-2-methylindole-4-carboxamide;CHEMBL3747513;CB 5083 [WHO-DD];CB-5083?;AC-29018;NSC786100;CS-5405;NSC-786100;JDP;AS-55872;AKOS025396184;NCGC00481317-01;SCHEMBL15421452;1-[4-(BENZYLAMINO)-5H,7H,8H-PYRANO[4,3-D]PYRIMIDIN-2-YL]-2-METHYLINDOLE-4-CARBOXAMIDE;1-(7,8-Dihydro-4-((phenylmethyl)amino)-5H-pyrano(4,3-d)pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide;1H-Indole-4-carboxamide, 1-(7,8-dihydro-4-((phenylmethyl)amino)-5H-pyrano(4,3-d)pyrimidin-2-yl)-2-methyl-;NCGC00481317-03;DA-71987;HMS3873E13
FormulaC24H23N5O2
M.Wt413.4717
SMILESO1C([H])([H])C([H])([H])C2=C(C(N([H])C([H])([H])C3C([H])=C([H])C([H])=C([H])C=3[H])=NC(=N2)N2C(C([H])([H])[H])=C([H])C3=C(C(N([H])[H])=O)C([H])=C([H])C([H])=C23)C1([H])[H]
Purity>98%
Storage2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Biological Activity

CB-5083 is a novel first in class, potent orally bio-available p97 inhibitor that disrupts cellular protein homeostasis and demonstrates anti-tumor activity in solid and hematological models . CB-5083 causes rapid and sustained accumulation of poly-ubiquitin in tumor xenografts after a single administration. CB-5083 showed activity to inhibit tumor growth in multiple rodent models of human cancer. Furthermore, CB-5083 appears to exhibit greater potency over current proteasome inhibitors that further validate targeting p97 and protein homeostasis in the treatment of cancer.

In Vitro

No in vitro data are provided in the current product source. Contact us for further information.

In Vivo

No in vivo data are provided in the current product source. Contact us for further information.

References & source

DC Chemicals original product information

Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.

Cart

Request quotation